Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2.

ABSTRACT:

Objectives

Among participants with Alzheimer's disease (AD) we estimated the minimal clinically important difference (MCID) in apathy symptom severity on three scales.

Design

Retrospective anchor- and distribution-based analyses of change in apathy symptom scores.

Setting

Apathy in Dementia Methylphenidate Trial (ADMET) and ADMET 2 randomized controlled trials conducted at three and ten clinics specialized in dementia care in United States and Canada, respectively.

Participants

Two hundred and sixty participants (60 ADMET, 200 ADMET 2) with clinically significant apathy in Alzheimer's disease.

Measurements

The Clinical Global Impression of Change in Apathy scale was used as the anchor measure and the MCID on the Neuropsychiatric Inventory - Apathy (NPI-A

SUBMITTER: Tumati S 

PROVIDER: S-EPMC11695175 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature